| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1056/NEJM199404213301608 |
| P698 | PubMed publication ID | 8133857 |
| P2093 | author name string | Moertel CG | |
| P433 | issue | 16 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | colorectal carcinoma | Q25493920 |
| colorectal cancer | Q188874 | ||
| P304 | page(s) | 1136-1142 | |
| P577 | publication date | 1994-04-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Chemotherapy for colorectal cancer | |
| P478 | volume | 330 |
| Q43573396 | 5-Fluorouracil induced Fas upregulation associated with apoptosis in liver metastases of colorectal cancer patients |
| Q92491341 | 5-fluorocytosine resistance is associated with hypermutation and alterations in capsule biosynthesis in Cryptococcus |
| Q77533706 | A multistep therapy with subcutaneous low dose recombinant interleukin-2, 5-fluorouracil and leucovorin prolongs the response of metastatic colorectal cancer patients: a pilot study |
| Q35836682 | A novel multiplexing, polymerase chain reaction-based assay for the analysis of chromosome 18q status in colorectal cancer. |
| Q77713974 | A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer |
| Q28352447 | A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil |
| Q33209415 | A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases |
| Q64380268 | Adenoviral-mediated transfer of Escherichia coli uracil phosphoribosyltransferase (UPRT) gene to modulate the sensitivity of the human colon cancer cells to 5-fluorouracil |
| Q72172773 | Adjuvant intraportal chemotherapy for colorectal cancer |
| Q61649344 | Adjuvant therapy for colorectal cancer |
| Q35036376 | Adjuvant therapy of cancers of the colon and rectum. |
| Q40476755 | Adjuvant treatment for colorectal cancer: ‘State of the Art’—messages from recent trials |
| Q41943341 | Aldose reductase inhibitor increases doxorubicin-sensitivity of colon cancer cells and decreases cardiotoxicity. |
| Q34349053 | Amplification of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy |
| Q33363615 | An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin |
| Q40423792 | An overview of adjuvant therapy for colorectal cancer |
| Q47271008 | Association of O6-Methylguanine-DNA Methyltransferase Protein Expression With Postoperative Prognosis and Adjuvant Chemotherapeutic Benefits Among Patients With Stage II or III Gastric Cancer |
| Q36106736 | Benefit-risk assessment of irinotecan in advanced colorectal cancer |
| Q77128658 | Bolus injection (2-4 min) versus short-term (10-20 min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: a prospective randomised trial. Nordic Gastrointestinal Tumour Adjuvant Therapy Group |
| Q43144287 | Cancer Treatment: The Cost Factor |
| Q36772441 | Changes in disease pattern and treatment outcome of colorectal cancer: a review of 5,474 cases in 20 years |
| Q24247840 | Chinese medical herbs for chemotherapy side effects and improving quality of life in colorectal cancer patients |
| Q36816741 | Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library |
| Q36901907 | Clinical gastroenterology |
| Q77948294 | Clinical significance of serum p53 antibody detection on chemosensitivity assay in human colorectal cancer |
| Q71657938 | Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins |
| Q40423899 | Colorectal cancer: Future population screening for early colorectal cancer |
| Q41481611 | Combined modality therapy of solid tumours. |
| Q73061706 | Combined preoperative irradiation and direct postoperative 5-fluorouracil without negative effects on early anastomotic healing in the rat colon |
| Q71170198 | Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors--Part one. Model projections for cost based on charges |
| Q73217037 | DCC expression and prognosis in colorectal cancer |
| Q31935218 | Determinants of prognosis and response to therapy in colorectal cancer |
| Q43578599 | Determination of microsatellite instability, p53 and K-RAS mutations in hepatic metastases from patients with colorectal cancer: relationship with response to 5-fluorouracil and survival |
| Q24561669 | Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients |
| Q43504494 | Disseminated single tumor cells as detected by real-time quantitative polymerase chain reaction represent a prognostic factor in patients undergoing surgery for colorectal cancer |
| Q64059625 | Down-regulation of miR-543 expression increases the sensitivity of colorectal cancer cells to 5-Fluorouracil through the PTEN/PI3K/AKT pathway |
| Q89984447 | Doxorubicin inhibits miR-140 expression and upregulates PD-L1 expression in HCT116 cells, opposite to its effects on MDA-MB-231 cells |
| Q37520284 | EZH2 promotes colorectal cancer stem-like cell expansion by activating p21cip1-Wnt/β-catenin signaling |
| Q33746878 | Efficacy of postoperative concurrent chemoradiation for resectable rectal cancer: a single institute experience |
| Q36981289 | Evaluation of preoperative C-reactive protein aids in predicting poor survival in patients with curative colorectal cancer with poor lymph node assessment |
| Q40886133 | Experimental chemotherapeutic agents for the treatment of colorectal carcinoma |
| Q36190651 | Expression of proliferating cell nuclear antigen and CD44 variant exon 6 in primary tumors and corresponding lymph node metastases of colorectal carcinoma with Dukes' stage C or D. |
| Q33877909 | Federation of European Cancer Societies. Full report. Economic evaluation in cancer care: questions and answers on how to alleviate conflicts between rising needs and expectations and tightening budgets |
| Q74646473 | First experience and technical aspects of isolated liver perfusion for extensive liver metastasis |
| Q74028608 | Five-day continuous infusion of 5-fluorouracil and pulsed folinic acid in patients with metastatic colorectal carcinoma: an effective second-line regimen |
| Q37626116 | Full costs of dispensing and administering fluorouracil chemotherapy for outpatients: A microcosting study |
| Q73258129 | Gastrointestinal cancer in the elderly |
| Q33870280 | Hepatobiliary surgery |
| Q24247800 | Herbal medicines for advanced colorectal cancer |
| Q53375647 | High frequency of activated K‐ras codon 15 mutant in colorectal carcinomas from Taiwanese patients |
| Q57758635 | High- versus low-dose levo-leucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer: A ‘GISCAD’ phase III study |
| Q71130407 | II--Cancer cachexia: treatments strategies |
| Q44759091 | Impact of positron emission tomography on strategy in liver resection for primary and secondary liver tumors |
| Q47981676 | Inhibition of fibroblast collagen synthesis and proliferation by levamisole and 5-fluorouracil |
| Q36136350 | Interleukin 2 and interferon alpha-2a do not improve anti-tumour activity of 5-fluorouracil in advanced colorectal cancer |
| Q24795784 | Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer |
| Q41188377 | Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer |
| Q30493555 | Is quality of colorectal cancer care good enough? Core measures development and its application for comparing hospitals in Taiwan |
| Q53431648 | Ki-ras mutations and prognosis in colorectal cancer. |
| Q35875398 | Liver directed therapies for colorectal cancer. |
| Q73481598 | Liver metastases from colorectal cancer |
| Q71816333 | Long-term survival in two cases of colorectal carcinoma following a new chemotherapy regimen and subsequent metastasectomy |
| Q42970964 | MRI and its importance in rectal cancer |
| Q90567429 | Metastatic Lymph Node Ratio (mLNR) is a Useful Parameter in the Prognosis of Colorectal Cancer; A Meta-Analysis for the Prognostic Role of mLNR |
| Q30485056 | Metastatic lymph node ratio (LNR) as a prognostic variable in colorectal cancer patients undergoing laparoscopic resection |
| Q35129256 | Mismatch repair proficiency and in vitro response to 5-fluorouracil |
| Q54599148 | Molecular detection of circulating tumor cells in the peripheral blood of patients with colorectal cancer using RT-PCR: significance of the prediction of postoperative metastasis. |
| Q36291281 | New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed ('Tomudex'). |
| Q37801028 | Oncoproteomics |
| Q91783635 | Outcomes of staged hepatectomies for liver malignancy |
| Q39356529 | Overexpression of the orotate phosphoribosyl-transferase gene enhances the effect of 5-Fluorouracil in head and neck squamous cell carcinoma in vitro |
| Q36616213 | Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trial |
| Q33688811 | Oxaliplatin: a review of its use in the management of metastatic colorectal cancer |
| Q36752170 | Pathology of rectal adenocarcinoma following preoperative adjuvant radiotherapy and chemotherapy |
| Q43807557 | Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer |
| Q36135282 | Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic colorectal cancer |
| Q77665233 | Phase II study of prolonged infusion of Taxol in patients with metastatic colorectal carcinoma |
| Q47249413 | Polyyne-Enriched Extract from Oplopanax elatus Significantly Ameliorates the Progression of Colon Carcinogenesis in ApcMin/+ Mice |
| Q45878491 | Potential role of DNA polymerase beta in gene therapy against cancer: a case for colorectal cancer |
| Q33320579 | Predictive value of Ki67 and p53 in locally advanced rectal cancer: correlation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapy |
| Q43901424 | Predictive value of thymidylate synthase expression in resected metastases of colorectal cancer |
| Q45991311 | Prognostic significance of allelic lost at chromosome 18q21 for stage II colorectal cancer. |
| Q47101055 | RAC3 influences the chemoresistance of colon cancer cells through autophagy and apoptosis inhibition. |
| Q35874711 | Radiofrequency ablation of liver tumours: systematic review |
| Q40419299 | Radioimmunoguided Surgery system improves survival for patients with recurrent colorectal cancer. |
| Q73379732 | Raltitrexed (Tomudex) in combination with 5-fluorouracil for the treatment of patients with advanced colorectal cancer: preliminary results from phase I clinical trials |
| Q34462838 | Raltitrexed. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer |
| Q33793871 | Recent advances: oncology |
| Q36903606 | Registration of drugs for treating cancer and HIV infection: a plea to carry out phase 3 trials before admission to the market |
| Q40798934 | Reliability and validity of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) quality of life instrument |
| Q38957845 | Remodelling of microRNAs in colorectal cancer by hypoxia alters metabolism profiles and 5-fluorouracil resistance |
| Q71656886 | Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy |
| Q40423849 | Role of leucovorin dosing and administration schedule |
| Q24792125 | Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer--a phase II study |
| Q50575635 | Short-term and long-term outcomes after simultaneous resection of colorectal malignancies and synchronous liver metastases. |
| Q42174340 | Soluplus--solubilized citrated camptothecin--a potential drug delivery strategy in colon cancer |
| Q35806757 | Surgical management of hepatic malignancy |
| Q39998713 | The effects of 5-fluorouracil and interferon-alpha on early healing of experimental intestinal anastomoses |
| Q34773758 | The efficacy of additional bevacizumab to cytotoxic chemotherapy regimens for the treatment of colorectal cancer: an updated meta-analysis for randomized trials |
| Q73093080 | The optimal 5-fluorouracil regimen for the adjuvant therapy of colon cancer: where to from here? |
| Q43932425 | Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy |
| Q44451243 | Thymidylate synthase inhibition triggers apoptosis via caspases-8 and -9 in both wild-type and mutant p53 colon cancer cell lines |
| Q37449160 | Thymidylate synthase, thymidine phosphorylase, VEGF and p53 protein expression in primary colorectal cancer for predicting response to 5-fluorouracil-based chemotherapy |
| Q57173342 | Treatment and Survival of Patients with Colon Cancer Aged 80 Years and Older: A EURECCA International Comparison |
| Q72676639 | Tumour pharmacokinetics?--we do need to know |
| Q73214550 | Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors |
Search more.